LivaNova PLC (NASDAQ:LIVN) Given Average Recommendation of “Moderate Buy” by Brokerages

LivaNova PLC (NASDAQ:LIVN) has received an average rating of “Moderate Buy” from the eleven analysts that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $81.3750.

A number of research firms recently weighed in on LIVN. KeyCorp lifted their price target on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Mizuho increased their price objective on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Zacks Research upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Robert W. Baird lowered their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th.

Insider Buying and Selling

In related news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director directly owned 7,228 shares in the company, valued at $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.35% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Several institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its stake in shares of LivaNova by 83.9% during the 4th quarter. SG Americas Securities LLC now owns 24,257 shares of the company’s stock valued at $1,493,000 after buying an additional 11,066 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in shares of LivaNova during the fourth quarter worth approximately $970,000. Tudor Investment Corp ET AL bought a new stake in shares of LivaNova in the third quarter worth $1,746,000. Peregrine Capital Management LLC bought a new stake in shares of LivaNova in the fourth quarter worth $3,830,000. Finally, F m Investments LLC raised its holdings in LivaNova by 46.9% in the fourth quarter. F m Investments LLC now owns 114,458 shares of the company’s stock valued at $7,043,000 after acquiring an additional 36,543 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Performance

NASDAQ LIVN opened at $78.19 on Friday. The company has a market cap of $4.29 billion, a P/E ratio of 40.10 and a beta of 0.86. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The stock has a 50-day moving average of $78.31 and a two-hundred day moving average of $69.54. LivaNova has a 1-year low of $41.01 and a 1-year high of $85.27.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.13. The business had revenue of $362.26 million during the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, analysts anticipate that LivaNova will post 3.73 EPS for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.